Point-of-care (POC) devices provide on-site disease diagnosis, particularly in resource-limited settings. Despite considerable progress in POC testing, the availability of commercial devices remains limited, primarily due to challenges in detection sensitivity and portability. Furthermore, advancements in existing POC devices are essential to better meet the needs of end-users. Herein, we present a colorimetric dual-functional tablet sensor using dextran-gold nanoparticles (dAuNPs) to detect and quantify uric acid and glucose levels in urine. Our tablet sensor combines the plasmonic and nanozyme properties of dAuNPs, resulting in highly sensitive detection of both biomarkers. Interestingly, we fabricated the nanogold tablet directly from the dAuNP solution without the addition of any external stabilizer or tablet-forming reagent, thus naming it a direct tablet. An enzyme-free approach was employed for uric acid detection, providing a wide detection range of 0.00187-7.8 mM and a low detection limit of 0.0037 mM, attributed to the hydrogen bonding between dextran and uric acid. On the other hand, the unique nanozyme properties of dAuNPs exhibited exclusive POx-mimetic activity for glucose detection ( = 0.106 mM and = 369.72 mM min), with a lower detection limit of 0.625 mM. Our dual-functional tablet offers exceptional substrate selectivity for the colorimetric-chromogenic assay of both uric acid and glucose. This dual-functionality not only provides a highly sensitive, selective, and cost-effective detection strategy for resource-limited settings but also introduces a new avenue for designing customizable plasmonic-nanozyme nanogold tablet sensors as a powerful tool for rapid diagnosis.